Eloralintide

The evidence is early but unusually well documented for a drug at this stage, with a receptor-pharmacology paper, a phase 1b and a phase 2 all published ^[1][2][3].

The phase 2 is the substantive result: 263 adults, 48 weeks, 46 US centres, mean body mass index 39.1. Placebo-adjusted weight change ran from 9 percent at 1 mg to 20 percent at 9 mg, against 0.4 percent on placebo ^[3]. Those are large numbers by any standard.

⚠️ Two limits on how far that can be pushed. All the receptor pharmacology comes from a single sponsor-generated paper and has not been independently replicated ^[1]. And there is no head-to-head trial against semaglutide, tirzepatide or cagrilintide; every comparison in circulation is cross-trial. A network meta-analysis that ranks eloralintide second among amylin agents describes its own findings as preliminary, sparse and low-certainty ^[4], and Lilly's own authors note that their tolerability comparison rests on indirect data ^[2].

One number that should not be quoted as a dose-response curve: nausea was 64 percent at 6 mg but 33 percent at 9 mg ^[3]. That is almost certainly noise from small groups rather than a real inversion.

Not an approved medicine anywhere; it is an investigational drug in phase 3 trials and there is no established consumer use. The safety picture comes from a 100-person phase 1b and a 263-person phase 2 ^[2][3].

Gastrointestinal effects are the main issue and they grow with exposure. Over twelve weeks nausea was 8.2 percent; over 48 weeks it reached 64 percent at 6 mg and 54 percent on one escalation arm ^[2][3]. Fatigue reached 43 to 46 percent in the higher arms and is consistently under-reported next to nausea. Injection-site reactions ran to 33 percent at 3 mg against 3.7 percent on placebo ^[2].

Two signals deserve naming. Heart rate fell in a clear dose-dependent way, by a mean of 14.4 bpm at 12 mg over twelve weeks, without symptomatic bradycardia or QTc changes so far ^[2]. And mood-related adverse events occurred at the higher doses, including depressed mood in 5.6 percent at 12 mg and one case of persistent depressive disorder; all three participants at 12 mg with mood events were taken off treatment, and the events resolved within days ^[2]. Anyone reading this as a weight-loss option should note that both of those emerged in small, short studies.

Unlike pramlintide, gastric emptying was only briefly slowed and returned to baseline by day 80 ^[2].

Amylin has been a drug target since the 1990s, when the native hormone's role in satiation was worked out and pramlintide was developed as a stable analogue. Pramlintide reached approval but never became widely used, partly because it required dosing at every meal and carried a severe hypoglycaemia warning when combined with insulin. The class was revived when long-acting analogues showed that weekly amylin agonism produced weight loss comparable to incretin drugs, and cagrilintide took that route by embracing activity at both amylin and calcitonin receptors. Eloralintide represents the alternative bet: that the calcitonin arm is responsible for the nausea and can be engineered away. Lilly took it into a full phase 3 programme, ENLIGHTEN, spanning obesity, type 2 diabetes, sleep apnoea and knee osteoarthritis, along with combination trials against tirzepatide.